Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.

Charles N BernsteinAruni TenakoonHarminder Singh Joseph W Windsor

Published in: Alimentary pharmacology & therapeutics (2021)

5ASA remains commonly prescribed in UC and CD. Rates of persistent use in UC are low. Once an anti-TNF or immunomodulator is initiated, continuation of 5ASA seems to add no benefit.

Keyphrases

rheumatoid arthritis